Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.
Fiedler W, DeDosso S, Cresta S, Weidmann J, Tessari A, Salzberg M, Dietrich B, Baumeister H, Goletz S, Gianni L, Sessa C. Fiedler W, et al. Among authors: dietrich b. Eur J Cancer. 2016 Aug;63:55-63. doi: 10.1016/j.ejca.2016.05.003. Epub 2016 Jun 7. Eur J Cancer. 2016. PMID: 27285281 Free article. Clinical Trial.
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.
Fiedler W, Cresta S, Schulze-Bergkamen H, De Dosso S, Weidmann J, Tessari A, Baumeister H, Danielczyk A, Dietrich B, Goletz S, Zurlo A, Salzberg M, Sessa C, Gianni L. Fiedler W, et al. Among authors: dietrich b. ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018. ESMO Open. 2018. PMID: 29464112 Free PMC article.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Klinghammer K, Fayette J, Kawecki A, Dietz A, Schafhausen P, Folprecht G, Rottey S, Debourdeau P, Lavernia J, Jacobs A, Ahrens-Fath I, Dietrich B, Baumeister H, Zurlo A, Ochsenreither S, Keilholz U. Klinghammer K, et al. Among authors: dietrich b. ESMO Open. 2021 Oct;6(5):100242. doi: 10.1016/j.esmoop.2021.100242. Epub 2021 Sep 2. ESMO Open. 2021. PMID: 34482179 Free PMC article. Clinical Trial.
Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF. Herrlinger KR, et al. Among authors: dietrich b. J Crohns Colitis. 2013 Sep;7(8):636-43. doi: 10.1016/j.crohns.2012.09.016. Epub 2012 Oct 16. J Crohns Colitis. 2013. PMID: 23078909 Clinical Trial.
Single dose human pharmacology of umespirone.
Holland RL, Wesnes K, Dietrich B. Holland RL, et al. Among authors: dietrich b. Eur J Clin Pharmacol. 1994;46(5):461-8. doi: 10.1007/BF00191912. Eur J Clin Pharmacol. 1994. PMID: 7957544 Clinical Trial.
184 results